These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10833076)

  • 41. Editorial: Imaging and the treatment of Crohn's perianal fistulas: to see is to believe.
    Schwartz DA
    Am J Gastroenterol; 2009 Dec; 104(12):2987-9. PubMed ID: 19956118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.
    Korzenik JR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):285-301, ix. PubMed ID: 15177539
    [TBL] [Abstract][Full Text] [Related]  

  • 43. THERAPIES FOR CROHN'S DISEASE: a clinical update.
    Sobrado CW; Leal RF; Sobrado LF
    Arq Gastroenterol; 2016; 53(3):206-11. PubMed ID: 27438429
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thalidomide is a therapeutic agent that is effective in inducing and maintaining endoscopic remission in adult CD patients.
    Zhu Z; Li M; Shu X; Bai A; Long S; Liu D; Lu N; Zhu X; Liao W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):210-216. PubMed ID: 27836485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low dose of thalidomide can be effective in advanced hepatocellular carcinoma.
    Chen SC; Tsai HJ; Jan CM; Wang YH; Chen LT
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1868-9. PubMed ID: 17074035
    [No Abstract]   [Full Text] [Related]  

  • 48. Review article: chronic active disease and maintaining remission in Crohn's disease.
    Kamm MA
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():102-5. PubMed ID: 15352904
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con.
    Griffiths AM
    Inflamm Bowel Dis; 2005 Feb; 11(2):200-2. PubMed ID: 15677915
    [No Abstract]   [Full Text] [Related]  

  • 50. [Oral aspects of Crohn's disease].
    Scheper HJ; Brand HS
    Ned Tijdschr Tandheelkd; 2000 Oct; 107(10):413-6. PubMed ID: 11383234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
    Felipez LM; Gokhale R; Tierney MP; Kirschner BS
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):28-33. PubMed ID: 21681114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spot diagnosis: eruptive melanocytic naevi during azathioprine therapy in Crohn's disease.
    Wonders J; De Boer NK; Van Weyenberg SJ
    J Crohns Colitis; 2012 Jun; 6(5):636. PubMed ID: 22402255
    [No Abstract]   [Full Text] [Related]  

  • 53. Tremor as dose dependent side-effect of azathioprine in remission patient with ileal Crohn's disease.
    Karaahmet F; Akinci H; Ayte R; Hamamci M; Coskun Y; Yuksel I
    J Crohns Colitis; 2013 Oct; 7(9):e404. PubMed ID: 23623283
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: balance.
    Jacobstein DA; Baldassano RN
    Inflamm Bowel Dis; 2005 Feb; 11(2):203-5. PubMed ID: 15677916
    [No Abstract]   [Full Text] [Related]  

  • 55. [Thalidomide in treatment of Crohn disease: a new approach for managing chronic inflammation?].
    Folwaczny C
    Z Gastroenterol; 2001 Feb; 39(2):195-8. PubMed ID: 11253513
    [No Abstract]   [Full Text] [Related]  

  • 56. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early combined immunosuppression in Crohn's disease.
    Herfarth H; Isaacs K
    Lancet; 2008 Jun; 371(9629):1995-6; author reply 1996-7. PubMed ID: 18555904
    [No Abstract]   [Full Text] [Related]  

  • 58. New life in a sleeper: thalidomide and Crohn's disease.
    Sands BE; Podolsky DK
    Gastroenterology; 1999 Dec; 117(6):1485-8. PubMed ID: 10579990
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
    Sandborn WJ; Tremaine WJ; Lawson GM
    Am J Gastroenterol; 1996 Jan; 91(1):37-43. PubMed ID: 8561141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tacrolimus in perianal manifestations of Crohn's disease].
    Nanaeva BA; Vardanian AV
    Eksp Klin Gastroenterol; 2013; (3):53-7. PubMed ID: 24294772
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.